First United Corporation reported a Q3 2026 net income of $7.2 million, up from $6.9 million in Q3 2025, driven by higher net interest income due to loan growth and better loan yields. The bank saw strong commercial and residential mortgage loan production and improved net interest margin to 4.05%. Despite inflation and interest rate uncertainties, the company maintained disciplined credit reserves and focused on expense management. Deposits and loans grew steadily, supporting positive momentum into Q4 2026.
First United Corporation's Q3 2026 results provide context for readers. For those following Financials, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Out of 142 priced Financials-sector US stocks, 42 rose and 99 fell. Notable movers include GPN at USD 84.48 with a 1-day change of +4.44% and 100% buy order activity, OXLC at USD 7.57 down 4.30% with 98% sell orders, and SOFI at USD 14.45 down 4.24% with 71% buy orders. Typical hold times range from 50 to 61 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
